Legend Biotech (LEGN) Gross Profit (2022 - 2026)

Legend Biotech (LEGN) has 5 years of Gross Profit data on file, last reported at $129.7 million in Q1 2026.

• Quarterly Gross Profit rose 3.35% year-over-year to $129.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $574.5 million (up 16.89% YoY) and the FY2024 annual result came in at $410.9 million, up 191.59% from the prior year.
• Gross Profit slipped to $129.7 million in Q1 2026, from $159.1 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $79.4 billion in Q4 2023 to a low of $723000.0 in Q1 2023.
• A 5-year average of $5.8 billion and a median of $112.4 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit soared 1701154.02% — and 2024, when it tumbled 99.85%.
• Tracing LEGN's Gross Profit over 5 years: stood at $4.7 million in 2022, then soared by 1701154.02% to $79.4 billion in 2023, then plunged by 99.85% to $117.1 million in 2024, then jumped by 35.84% to $159.1 million in 2025, then retreated by 18.46% to $129.7 million in 2026.
• The last three Gross Profit figures came in at $129.7 million (Q1 2026), $159.1 million (Q3 2025), and $160.2 million (Q2 2025), per Business Quant data.